Physician profile
Arun Bhandari
NPI 1730161878
$103,277.31
in general payments reported to CMS, 2019-2025
71 companies · $6,722 in 2025
The $6,722 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $14K · 2021: $8,568 · 2022: $31K · 2023: $14K · 2024: $14K · 2025: $6,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $25K · Food and Beverage: $5,382 · Honoraria: $3,136 · Travel and Lodging: $986 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $25,067.00 |
| Food and Beverage | $5,381.93 |
| Honoraria | $3,135.50 |
| Travel and Lodging | $985.92 |
| Education | $108.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $20,225.43 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $12,247.33 | 2022-2024 | Jemperli, Zejula |
| Lilly USA, LLC | $10,218.88 | 2021-2024 | Jaypirca, Retevmo, Verzenio |
| Kite Pharma, INC. | $7,633.68 | 2019-2025 | Yescarta |
| Regeneron Healthcare Solutions, INC. | $4,755.46 | 2021-2025 | Libtayo |
| Acrotech Biopharma INC. | $4,723.57 | 2023-2024 | Beleodaq |
| Genzyme Corporation | $4,631.56 | 2019-2024 | |
| Incyte Corporation | $4,179.11 | 2020-2025 | Jakafi |
| Seagen INC. | $3,203.42 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Tesaro, INC. | $3,049.91 | 2019 | |
| Pharmaessentia USA Corporation | $2,179.92 | 2023-2025 | Besremi |
| Invivyd INC | $2,123.02 | 2024-2025 | Pemgarda |
| Pfizer INC. | $1,881.11 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $1,872.94 | 2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $1,657.81 | 2020-2025 | Opdivo |
Show all 71 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $1,550.00 | 2020 | |
| Cti Biopharma Corp. | $1,500.00 | 2022 | |
| Taiho Oncology, INC. | $1,356.04 | 2020-2024 | |
| Daiichi Sankyo INC. | $1,299.55 | 2022-2025 | Vanflyta, Enhertu, Datroway |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,278.51 | 2019-2025 | |
| Janssen Biotech, INC. | $1,205.01 | 2020-2025 | Erleada, Darzalex, Tecvayli |
| Blueprint Medicines Corporation | $1,198.66 | 2021-2024 | Ayvakit |
| Coherus Oncology, INC. | $1,088.00 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,076.90 | 2019-2025 | |
| Amgen INC. | $835.24 | 2019-2025 | Evenity, Prolia, Nplate |
| Janssen Scientific Affairs, LLC | $817.50 | 2023 | Erleada |
| Macrogenics, INC. | $800.00 | 2021 | |
| Kyowa Kirin, INC. | $772.92 | 2021-2023 | Poteligeo |
| Novartis Pharmaceuticals Corporation | $559.21 | 2020-2025 | |
| Tersera Therapeutics LLC | $419.00 | 2023 | Zoladex |
| Celgene Corporation | $284.95 | 2022-2024 | Reblozyl, Pomalyst |
| Sobi, INC | $192.41 | 2022-2025 | |
| Abbvie INC. | $183.67 | 2023-2025 | Venclexta |
| Abbott Laboratories | $170.71 | 2020 | |
| Puma Biotechnology, INC. | $129.60 | 2022-2025 | |
| Pharmacosmos Therapeutics INC. | $123.74 | 2023-2024 | Monoferric |
| Astellas Pharma US INC | $121.37 | 2023-2025 | Padcev, Veozah, Xtandi |
| Tempus Ai, INC | $116.94 | 2024 | Xt Cdx |
| Beigene USA, INC. | $106.43 | 2021-2023 | Brukinsa |
| Takeda Pharmaceuticals U.S.A., INC. | $105.50 | 2023-2025 | Iclusig, Ninlaro |
| Cardinal Health 110 LLC | $100.00 | 2020 | |
| Clovis Oncology, INC. | $99.00 | 2019 | |
| Mirati Therapeutics, INC. | $93.18 | 2023-2024 | Krazati |
| Jazz Pharmaceuticals INC. | $86.47 | 2023-2024 | Zepzelca |
| Syndax Pharmaceuticals, INC. | $85.92 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $68.36 | 2023-2024 | Onivyde, Somatuline Depot, Tazverik |
| Ge Healthcare | $65.51 | 2022 | |
| Pharmacyclics LLC, An Abbvie Company | $65.43 | 2022 | |
| Gilead Sciences, INC. | $62.23 | 2021-2025 | Trodelvy |
| Sun Pharmaceutical Industries INC. | $60.98 | 2021 | |
| Exelixis INC. | $57.93 | 2022-2023 | Cabometyx |
| Fresenius Kabi USA, LLC | $53.64 | 2024-2025 | Stimufend |
| Genentech USA, INC. | $46.93 | 2023 | Polivy, Lunsumio |
| Spectrum Pharmaceuticals INC. | $44.96 | 2025 | Rolvedon |
| Merck Sharp & Dohme LLC | $43.08 | 2021-2024 | Keytruda |
| Menarini Silicon Biosystems, INC. | $39.11 | 2025 | |
| Aveo Pharmaceuticals, INC. | $38.51 | 2025 | |
| Stemline Therapeutics INC. | $29.68 | 2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $28.97 | 2022 | |
| Alnylam Pharmaceuticals INC. | $26.56 | 2025 | Givlaari |
| G1 Therapeutics, INC. | $24.70 | 2023 | Cosela |
| Azurity Pharmaceuticals, INC. | $24.47 | 2025 | Danziten |
| Amneal Pharmaceuticals LLC | $24.01 | 2023 | Avastin |
| Csl Behring | $20.60 | 2024 | Privigen |
| Rigel Pharmaceuticals, INC. | $19.13 | 2024 | Rezlidhia, Tavalisse |
| Eisai INC. | $18.93 | 2019 | |
| Eusa Pharma (US) LLC | $17.19 | 2022 | |
| Adc Therapeutics America, INC. | $15.55 | 2025 | |
| Myriad Genetic Laboratories, INC. | $14.78 | 2023 | Mychoice Cdx |
| Octapharma USA, INC. | $14.70 | 2024 | Octagam Immune Globulin (Human) |
| Morphosys, US INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arun Bhandari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.